Carcinoma of unknown primary · 17 regimens
Cost vs Efficacy · 11 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Erlotinib and Bevacizumab Variant #01 | — | R 52 071 | 28d | ~16.4 mo | ~49.1 mo | ~18 | ~R 937 282 PFS proxy · indirect | 7 |
Cisplatin and Gemcitabine (GC) Variant #34 | — | R 15 338 | 56d | ~6.9 mo | ~11.9 mo | ~4 | ~R 61 352 PFS proxy · indirect | 59 |
GCP Variant #01 | — | R 8 155 | 21d | ~16.0 mo | ~50.9 mo | ~24 | ~R 195 716 PFS proxy · indirect | 3 |
Carboplatin and Paclitaxel (CP) Variant #38 | — | R 5 031 | 21d | ~8.9 mo | ~13.3 mo | ~13 | ~R 65 399 PFS proxy · indirect | 114 |
Docetaxel and Gemcitabine Variant #01 | — | R 4 912 | 21d | ~6.2 mo | ~26.9 mo | ~9 | ~R 44 207 PFS proxy · indirect | 3 |
PCE Variant #01 | — | R 4 157 | 21d | — | — | — | — | — |
Gemcitabine and Irinotecan Variant #01 | — | R 4 125 | 21d | — | — | — | — | — |
Carboplatin and Gemcitabine (GCb) Variant #01 | — | R 3 663 | 21d | ~6.3 mo | ~12.1 mo | ~10 | ~R 36 631 PFS proxy · indirect | 38 |
Carboplatin and Docetaxel (DCb) Variant #01 | — | R 3 300 | 21d | ~4.7 mo | ~22.3 mo | ~7 | ~R 23 101 PFS proxy · indirect | 4 |
BEP Variant #01 | — | R 2 244 | 21d | — | — | — | — | — |
Cisplatin and Irinotecan (IC) N/A - secondary systemic drug | — | R 743 | 42d | ~3.8 mo | ~12.9 mo | ~3 | ~R 2 230 PFS proxy · indirect | 10 |
Cisplatin monotherapy Variant #16 | — | R 650 | 28d | ~2.1 mo | ~8.7 mo | ~3 | ~R 1 950 PFS proxy · indirect | 8 |
PCF N/A - secondary systemic drug | — | R 604 | 21d | — | — | — | — | — |
Cisplatin and Docetaxel (DC) N/A - secondary systemic drug | — | R 449 | 21d | ~5.2 mo | ~13.0 mo | ~8 | ~R 3 594 PFS proxy · indirect | 11 |
DCF N/A - secondary systemic drug | — | R 228 | 21d | ~12.8 mo | ~18.8 mo | ~19 | ~R 4 323 PFS proxy · indirect | 10 |
Carboplatin and Gemcitabine (GCb) and Paclitaxel N/A - secondary systemic drug | — | R 36 | 21d | — | ~10.8 mo | — | — | 1 |
Nivolumab monotherapy Variant #01 Partial | — | — | 14d | ~4.6 mo | ~12.2 mo | ~11 | — | 28 |
17 of 17 regimens shown